PTC Confident About Commercial Prospects For Gene Therapy Upstaza
One-Time Injection Gets CHMP Nod For AADC Deficiency
Executive Summary
PTC CEO Stuart Peltz tells Scrip that cost watchdogs are likely to look favorably on the firm’s transformational gene therapy for a distressing rare brain disorder in children who could not even lift their heads before treatment.
You may also be interested in...
Finance Watch: PTC Secures Up To $1bn In Funding From Blackstone
Public Company Edition: PTC will get $350m up front as part of an initial $500m commitment. Also, while Biohaven and Vaxcyte launched traditional follow-on offerings, Recursion and Agios took the private placement and royalty sale routes, while others revealed job cuts and other strategic updates.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: etrasimod comes through for Pfizer; PTC confident on gene therapy; could CAR-Ts roll into the community setting; the attractions of Boston for Korean bioventures; and Ukraine war may claim Sputnik casualties.
FDA Leader: We Need To Remove Surprises From Gene Therapy Development
Embattled gene therapy companies will take comfort from desire of FDA and EMA help smooth the process of bringing the novel treatments to market.